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Objective: Medicines with limited evidence of effectiveness are prime candidates for 42 
disinvestment. However, investment in further research may be preferable to de-43 
implementation, given that the absence of evidence is not evidence of absence, and research 44 
can inform formulary decisions. A case in point is liothyronine, which is sometimes 45 
prescribed to levothyroxine-treated patients who continue to experience hypothyroid 46 
symptoms. It is a putative low value medicine, associated with uncertainties in both clinical 47 
and cost effectiveness. The aim was to assess the cost-effectiveness of liothyronine in this 48 
context, and estimate the value of conducting further research. 49 
Design: Cost utility and value of information analyses. 50 
Setting: Primary care within the National Health Service in the UK. 51 
Participants: Fifty-four levothyroxine-treated patients with persistent symptoms of 52 
hypothyroidism. 53 
Interventions: Liothyronine plus levothyroxine versus levothyroxine alone. 54 
Primary and secondary outcome measures: Incremental cost per quality-adjusted life year 55 
(QALY) gained, and the expected monetary value of sample information. 56 
Results: 20/54 (37%) of patients who responded to the survey reported severe problems in 57 
carrying out usual activities of everyday living and 12/54 (22%) reported severe anxiety or 58 
depression symptoms. Mean (SD) utility was 0.53 (0.23). The differences in expected total, 59 
10-year costs and QALYs between a treatment strategy of liothyronine/levothyroxine 60 
combination therapy, and levothyroxine alone, was £12,053 and 1.014, respectively. The 61 
incremental cost effectiveness ratio of £11,881 per QALY gained was sensitive to the price of 62 
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liothyronine. The probability of liothyronine/levothyroxine combination therapy being cost 63 
effective at a threshold of £20,000 per QALY was 0.56. The value of reducing uncertainty in 64 
the efficacy of treatment was £3.64m per year in the UK. 65 
Conclusions: A definitive clinical trial to confirm clinical effectiveness may be preferable to 66 
immediate disinvestment, and would be justified given the value of the information gained far 67 
exceeds the cost. 68 
 69 
Keywords: 70 
Cost-effectiveness analysis, value of information analysis, disinvestment, liothryonine, 71 
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Strengths and limitations of this study 73 
• This first analysis of health utilities and costs relating to treatment-unresponsive 74 
hypothyroidism addresses a decision problem which is pertinent to the NHS across the 75 
UK 76 
• The methods provide a framework for deciding whether investing in further research in 77 
order to reduce uncertainty in the clinical and cost-effectiveness of medicines presumed 78 
to be of low value, is preferable to formulary delisting 79 
• Estimates of resource utilisation and treatment effectiveness were based on the opinions 80 
of a sample of general practitioners and endocrinologists 81 
• The decision analytic model was a simple representation of what is a complex clinical 82 
management problem, often involving misdiagnosis, co-morbidities and multiple 83 
referrals, investigations and treatments 84 




Disinvestment from health care interventions and practices that are considered to offer no or 87 
low value is a strategy being used increasingly by healthcare systems around the world in 88 
response to unprecedented pressures on budgets [1]. Within the National Health Service 89 
(NHS) in the UK, there has been a specific focus on older medicines [2] – such as those 90 
which gained marketing authorisation in an era when the evidential standards were lower; or 91 
which have been largely supplanted by newer, more effective or safer medicines; or whose 92 
use has become marginalised resulting in variation in care, or monopoly of supply leading to 93 
price inflation. Health technology reassessment (HTR) describes the process of judging the 94 
value of such medicines, and determining whether they warrant continued use, more 95 
expanded use or disinvestment (deimplementation). HTR methods may also allow for an 96 
assessment of the value of conducting further research to reduce the uncertainty surrounding 97 
a medicine’s clinical and cost-effectiveness. In such cases, continuing the status quo may be 98 
reasonably justified while new evidence accrues.  99 
Liothyronine is an epitome, first licensed for the management of hypothyroidism in 1956, but 100 
replaced by levothyroxine which offers more favourable dosing and stable serum thyroid 101 
hormone concentrations. However, 5-10% of levothyroxine-treated patients continue to 102 
experience profound and sometimes disabling symptoms, such as fatigue, depression and 103 
impaired cognition, despite achieving thyroid hormone concentrations within reference range 104 
[3]. A proportion of these patients are prescribed liothyronine, usually in addition to 105 
levothyroxine [3]. 106 
Clinical guidelines advise against the routine prescribing of liothyronine. The European 107 
Thyroid Association recommends that liothyronine/levothyroxine combination therapy might 108 
be considered as an experimental approach in hypothyroidism for patients who are adherent 109 
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to levothyroxine, yet experience persistent symptoms despite serum thyroid stimulating 110 
hormone (TSH) values within the reference range [4]. The American Thyroid Association 111 
notes that there is currently insufficient evidence to support the routine use of combination 112 
therapy outside a formal clinical or N-of-1 trial [5]; and largely based on these guidelines, the 113 
British Thyroid Association recommends that liothyronine/levothyroxine combination 114 
therapy may only be considered by endocrinologists for patients who have unambiguously 115 
not benefited from levothyroxine [6]. 116 
The use of liothyronine in the UK has been further discouraged because of significant price 117 
inflation due to monopoly status of the generic supplier since it was de-branded in 2007. The 118 
current price of 28 tablets of 20μg liothyronine is £165.18, compared with £26.15 in 2010. 119 
This resulted in the NHS listing liothyronine as a medicine that should not be prescribed 120 
routinely in primary care [7,8]. 121 
Clinical guidelines acknowledge the limited evidence-base for liothyronine. While thirteen 122 
trials of combination versus levothyroxine monotherapy therapy have been reported [9], the 123 
majority are underpowered, some are unlikely to have tested the correct dose of liothyronine, 124 
and none restricted recruitment to patients who did not feel significantly better on 125 
levothyroxine alone [3,9-12]. This latter point could explain why liothyronine/levothyroxine 126 
combination therapy has not demonstrated superiority, even in the larger trials. Walsh et al. 127 
[13] found no statistically significant difference in patient wellbeing, quality of life or 128 
cognitive function. Appelhof et al. [14] reported that patients preferred combination therapy 129 
but there were no differences in clinical endpoints; and Saravanan et al. [15] did not find a 130 
significant difference in General Health Questionnaire-12 scores. 131 
The National Institute for Health and Care Excellence (NICE), in its clinical guideline on 132 
thyroid disease [16], recommended that further research should be undertaken on the clinical- 133 
8 
 
and cost-effectiveness of liothyronine/levothyroxine combination therapy compared with 134 
levothyroxine for people with hypothyroidism whose symptoms have not responded 135 
sufficiently to levothyroxine alone. However, a formal analysis of its clinical and cost-136 
effectiveness was not undertaken. 137 
The aim of the present study was to undertake an HTR focusing on the cost-effectiveness of 138 
liothyronine in this context and adopting the perspective of the NHS in the UK, to assess the 139 
value of conducting further research to ascertain the clinical effectiveness of liothyronine as a 140 




An economic model was developed to estimate the cost effectiveness (incremental cost per 145 
quality-adjusted life year, QALY gained) of liothyronine/levothyroxine combination therapy. 146 
Health utilities were obtained from a survey of hypothyroid patients. The likelihood of the 147 
addition of liothyronine in returning patients to age-matched population health was based on 148 
the survey of endocrinologists and general practitioners, who also provided estimates of 149 
patients’ use of health care resources. The perspective of the NHS was adopted, with a 10-150 
year time horizon of analysis. The economic analysis is reported in accordance with the 151 
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement [17]. 152 
Population 153 
The model represented a population of patients diagnosed with primary hypothyroidism who 154 
remain actively symptomatic with levothyroxine despite being adherent with free T4 within 155 
normal ranges (9-25 pmol/l) and euthyroid serum TSH concentrations (0.4-4.0 mU/l). The 156 
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cohort represented adults aged 50 years upon entry to the model, consistent with the mean 157 
age of diagnosis of hypothyroidism [18]. The simulated cohort was followed for 10 years, a 158 
period considered to be sufficient to capture differences in costs and outcomes between the 159 
treatment strategies. 160 
Intervention 161 
In the model, patients could continue levothyroxine alone, representing usual care in the 162 
majority of cases, or alternatively trial a 3-month period of liothyronine in combination with 163 
levothyroxine [6]. Following the 3-month period, responders may continue 164 
liothyronine/levothyroxine combination therapy for the remainder of the 10-year time horizon 165 
of analysis. Non-responders discontinue liothyronine and revert to levothyroxine 166 
monotherapy. The base-case analysis assumed an average ratio of 1:3 [16], corresponding to 167 
a daily dose of 17μg of liothyronine and 50μg of levothyroxine. The dose of levothyroxine 168 
monotherapy was assumed to be 100μg/day. 169 
Model structure 170 
A decision tree was constructed (Figure S1, Supplementary appendix), in which 10-year 171 
expected costs and quality-adjusted life years (QALYs) were estimated, and discounted at 172 
3.5% per annum [19].  173 
Health utilities 174 
Literature searches did not identify any relevant health utility data [20]. Self-selecting people 175 
who reported to be clinically unresponsive to levothyroxine alone despite being 176 
biochemically euthyroid were recruited to a survey that was advertisement via social media, 177 
and hosted on the website of the charity Thyroid UK. Consent was obtained within the online 178 
form, following a full explanation of the purpose and nature of the survey. Those who 179 
consented were invited to complete the online survey, which included the validated, multi-180 
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attribute health utility instrument, the EuroQol EQ-5D-5L questionnaire and accompanying 181 
EQ-VAS (visual analogue scale) [21]. The EQ-5D-5L questionnaire asks about 5 dimensions 182 
of health (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each 183 
dimension has 5 levels: no problems, slight problems, moderate problems, severe problems 184 
and extreme problems. EQ-5D-5L profiles were converted to EQ-5D-5L index values based 185 
on the EQ-5D-5L/3L cross walk value set for the UK [22] in line with current best practice 186 
[23]. Utility scores of 0 and 1 correspond to death and full health, respectively. 187 
In the model, patients who responded to liothyronine/levothyroxine combination therapy 188 
were assumed to adopt age-matched population norm EQ-5D-3L utility values [24,25]. 189 
Patients entering the model, and remaining symptomatic to either levothyroxine monotherapy 190 
or in addition to liothyronine were assumed to experience the health utilities of the sample 191 
surveyed. 192 
Mortality 193 
The model applied standard mortality rates of the UK general population for 2016/18 [26], on 194 
the basis of no evidence of mortality differences in treated hypothyroid patients [18,27]. 195 
Resource use 196 
There was no published data on NHS health care resource use and costs for the indication 197 
under consideration. Therefore, a survey of endocrinologists and general practitioners across 198 
Wales and the North West of England was conducted to estimate resource use in patients who 199 
were in each of the three branches of the decision analytic model. Clinicians recruited by one 200 
of the authors (AH) or the All Wales Therapeutic and Toxicology Centre were contacted and 201 
invited to complete the questionnaire. Categories of resource use included contacts with 202 
healthcare professionals (general practitioner GP surgery visits, endocrinologist outpatient 203 
appointments and phlebotomists), thyroid function and associated tests (including TSH, free 204 
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T4, free T3, TSH receptor antibodies TRAb, and thyroid peroxidase TPO antibody testing), 205 
and safety monitoring tests (including, electrocardiogram, echocardiogram, bone 206 
densitometry).  207 
Unit costs 208 
The unit costs of NHS care were derived from the NICE guideline [16] and from standard 209 
sources [25,28], based on a 2018/19 cost year (Table 1), and reported in British pounds (£). 210 
Clinical effectiveness 211 
Published clinical trials and systematic reviews [9,16] were assessed for relevant data on the 212 
clinical effectiveness of liothyronine/levothyroxine combination therapy. None of the trials 213 
restricted their inclusion criteria to (or performed a sub-group analysis of) the population of 214 
interest and were therefore not considered relevant to inform the decision problem. A survey 215 
was therefore undertaken, to elicit plausible estimates of treatment effect from 216 
endocrinologists and general practitioners experienced in prescribing liothyronine [29]. They 217 
were asked what proportion of patients would be expected to improve following a 3-month 218 
trial period with liothyronine/levothyroxine combination therapy. The mean of all responses 219 
was used in the base-case analysis. 220 
Analysis 221 
In the base-case deterministic analysis, the expected costs and QALYs were compared 222 
incrementally to estimate the incremental cost-effectiveness ratio (ICER): 223 
ICER =  CostLIOTHYRONINE + LEVOTHYROXINE – CostLEVOTHYROXINE 224 
 QALYLIOTHYRONINE + LEVOTHYROXINE – QALYLEVOTHYROXINE 225 
Uncertainty analyses 226 
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A series of one-way sensitivity analyses was performed to assess the impact on the ICER of 227 
varying: the probability that patients respond following a 3-month trial of 228 
liothyronine/levothyroxine combination therapy; the time horizon of analysis; discount rates 229 
(0% and 6% per annum); the cost of liothyronine; the age of patients in the cohort; and of 230 
using EQ-VAS for utility in patients who remain symptomatic. 231 
The extent to which the ICER changed when simultaneously varying the probability of 232 
patients responding to liothyronine/levothyroxine combination therapy, and the annual cost of 233 
liothyronine, was assessed in a two-way sensitivity analysis. 234 
A probabilistic sensitivity analysis (PSA) was conducted for the simultaneous consideration 235 
of uncertainty in all model parameters (costs, QALYs and probability of treatment response). 236 
Uncertainties in these parameters were represented by relevant distributions and using Monte 237 
Carlo simulation with 10,000 replications to establish the probability of 238 
liothyronine/levothyroxine combination therapy being cost-effective for different threshold 239 
values of willingness to pay. Cost effectiveness acceptability curves [30] were constructed to 240 
represent this relationship and to facilitate comparison with the NICE thresholds of £20,000 241 
to £30,000 per QALY operating in the UK [19]. 242 
For the PSA, the number of prescriptions and costs of medicines were assumed to be fixed. 243 
For other items of resource use, annual quantities (and the initial 3 months in the case of 244 
liothyronine) were sampled from gamma distributions with means and standard deviations 245 
(SD) based on responses to the survey. These were each multiplied by their respective unit 246 
costs. Utilities representing the general population norms were sampled from beta 247 
distributions with means and SD as reported by Kind et al [24]. EQ-5D utility values (U) 248 
from the sample of hypothyroid patients were transformed (1-U), and the parameters of a 249 
gamma distribution (α, β) were estimated via maximum likelihood for (1-U) ~ Gamma(α, β). 250 
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The probability of responding to liothyronine/levothyroxine combination therapy was 251 
sampled from a beta distribution fitted to the reported range of expert opinions. 252 
Value of information analysis 253 
In order to determine the value of conducting additional research to reduce uncertainties in 254 
the model, a value of information analysis was conducted using the Sheffield Accelerated 255 
Value of Information (SAVI) [31]. Value of information analysis aids understanding of the 256 
acceptability of the existing uncertainty compared with the investment needed to obtain the 257 
necessary evidence that would reduce that uncertainty, enabling a decision to be made with 258 
existing information or whether to invest in further research to inform decisions with more 259 
evidence. We calculated the Expected Value of Perfect Information (EVPI) per person and 260 
overall, the Expected Value of Partially Perfect Information (EVPPI) to identify those 261 
parameters that contribute most to the decision uncertainty, and the Expected Value of 262 
Sample Information (EVSI) to measure the potential value of a future clinical trial. 263 
Software 264 
The cost-effectiveness analysis and sensitivity analyses were performed in Microsoft Excel® 265 
2016.  Macros used to run simulations for the PSA were written in Visual Basic for 266 
Applications. The value of information analysis was conducted using SAVI [31]. 267 
Model validation 268 
Validation checks were made in accordance with the AdViSHE tool [32]. Development and 269 
validation of the model structure was in consultation with endocrinologists, and based on best 270 
practice and clinical guidelines for trialling liothyronine prior to its long term prescribing. 271 
The face validity of data used as inputs to the model was both a function of findings from 272 
systematic review of the clinical literature, and the opinions of clinicians (endocrinologists 273 
and GPs) with expertise (internationally renowned in two cases) and /or experience in 274 
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treating patients with liothyronine. Extreme value testing and consistency checks were made 275 
to ensure there were no coding errors. The analysis and outputs were subject to review of 276 
external validity by members of the All Wales Prescribing Advisory Group, the All Wales 277 
Therapeutics and Toxicology Centre, and the All Wales Medicines Strategy Group. 278 
Patient and Public Involvement 279 
This research was designed and performed without active patient or public involvement. 280 
Results 281 
Health utilities 282 
Responses were available from 54 people with hypothyroidism. Mean (SD, minimum, 283 
maximum) utility was 0.53 (0.23, 0.00, 0.84).  44/54 (81%) individuals reported having 284 
moderate problems (EQ-5D-5L level scores ≥3) in at least one attribute, most often their 285 
ability to perform usual activities, and anxiety or depression; 24/54 (44%) reported severe 286 
problems (level scores ≥4) in at least one attribute; and 9/54 (19%) reported extreme 287 
problems (level 5) in at least one attribute (Figure 1).  Of note, 37% reported severe problems 288 
in carrying out usual activities of everyday living and 22% reported the regular occurrence of 289 
severe anxiety or depression symptoms. The mean (SD, minimum, maximum) EQ-VAS score 290 
was 49.3 (17.2, 5.0, 90.0). 291 
Resource use and costs 292 
Five endocrinologists and 3 GPs responded to the survey. They reported patients who remain 293 
symptomatic on levothyroxine monotherapy to visit their GPs on 5.5 instances a year on 294 
average, their endocrinologist 3.1 times, and receive 5.9 thyroid function tests annually 295 
(Table 1). For patients who respond to combination therapy, these frequencies were reported 296 
to reduce to 2.4, 2.6, and 4.8 times per year, respectively. 297 
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Incremental analysis 298 
Total and disaggregated costs are reported in Table 2.  The single largest cost item was 299 
liothyronine, followed by hospital outpatient endocrinologist visits. The difference in 300 
expected total, 10-year costs between a treatment strategy of liothyronine/levothyroxine 301 
combination therapy, and levothyroxine alone, was £12,053, indicating that combination 302 
therapy is more expensive overall. Patients were modelled to experience 5.559 discounted 303 
QALYs following a decision to initiate a 3-month trial of liothyronine in addition to 304 
levothyroxine (and continue treatment in those who respond). This compares with 4.545 305 
QALYs for the current standard of care based on levothyroxine monotherapy. The resulting 306 
incremental cost-effectiveness ratio is £11,881 per QALY gained (Table 3). 307 
The ICER was insensitive to changes in several parameter estimates in one-way sensitivity 308 
analyses (Table 4). However, there is considerable uncertainty in the probability of treatment 309 
response, which translated to sensitivity in the ICER, increasing to £20,816 per QALY gained 310 
if only 5% of patients respond. The key driver of cost-effectiveness was the price of 311 
liothyronine. The multivariate sensitivity analysis (Figure S2, Supplementary appendix) 312 
illustrates the combinations of prices and effectiveness probabilities of 313 
liothyronine/levothyroxine combination therapy that result in ICERs that are cost-effective. 314 
For example, based on a 5% chance of treatment response, liothyronine/levothyroxine is cost-315 
effective up to a cost of £3,245 per annum (which is marginally less than the current annual 316 
cost of £3,366).  317 
Probabilistic sensitivity analysis 318 
Parameter estimates and specification of the probabilistic sensitivity analysis are presented in 319 
Table 5, and the results are depicted as a cost-effectiveness plane and cost-effectiveness 320 
acceptability curve in Figure 2.  The PSA indicated the probabilities of 321 
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liothyronine/levothyroxine combination therapy being cost-effective at thresholds of £20,000 322 
and £30,000 per QALY, as 0.557 and 0.642, respectively. The probabilities of being cost-323 
saving is 0.060, and in generating QALY gains, is 0.939. 324 
Value of information analysis 325 
Based on a £20,000 per QALY threshold for cost-effectiveness, the overall EVPI per eligible 326 
patient is estimated at £2,521. This is equivalent to 0.126 QALYs per person when valuing 327 
uncertainty on the QALY scale. Assuming an annual number of patients potentially eligible 328 
for liothyronine of 10,000, the overall EVPI is £25,206,183 per year for the UK. If it is 329 
assumed that the relevance of the present analysis persists for 10 years, the overall expected 330 
value of removing decision uncertainty for the UK would in total be £252m. The EVPPI was 331 
highest for utilities in patients who remain symptomatic (£1,902 per person), followed by the 332 
probability of liothyronine combination therapy being clinically effective (£328 per person). 333 
A conservative, 1-parameter (probability of treatment response) population EVSI yielded an 334 
estimate of £3,644,000 per year for a clinical trial of 300 patients. 335 
 336 
Discussion 337 
Disinvestment of many medicines considered to be low in value has proven to be difficult to 338 
achieve in practice [1]. This is due to a number of reasons [33], including system factors such 339 
as a lack of funding or incentives for change, lack of skills in change management, and 340 
organisational challenges e.g. in relation to reimbursement. There is also patient and 341 
healthcare professional reluctance or consideration of it as a cost-saving exercise only; the 342 
belief that removal of a medicine will result in loss of benefit, or that deimplementation has 343 
greater disadvantage than to not accept a new medicine with similar value; and, in several 344 
cases, a lack of convincing evidence of no harm from withdrawal and no benefit. 345 
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In the case of liothyronine, there are disparate clinical views, high costs and a lack of robust 346 
evidence of clinical effectiveness. However, there is also a large unmet need with only 347 
unlicensed natural desiccated thyroid extract as an alternative [9], and a high demand from a 348 
significant minority of people with hypothyroidism who are seemingly unresponsive to 349 
levothyroxine with associated very low health-related quality of life compared to the general 350 
population [34]. Many report dissatisfaction with treatment and experience symptoms 351 
consistent with overt hypothyroidism, including fatigue, memory problems, cognitive 352 
dysfunction, feeling cold and weight gain [3,35]. Our survey indicated their mean utility 353 
value is 0.53 which makes these individuals comparable in terms of their health status, to 354 
patients with lung cancer, or acute cerebrovascular disease and would rank in the bottom 355 
decile of 100 chronic diseases [36]. 356 
The economic analysis suggests that liothyronine/levothyroxine combination therapy may 357 
represent a cost-effective treatment option for patients who remain symptomatic with 358 
levothyroxine alone despite achieving free T4 and TSH concentrations within the reference 359 
ranges. At £11,881 per QALY gained, the ICER fell below the NICE cost-effectiveness 360 
threshold of £20,000 per QALY. However, the probability of liothyronine/levothyroxine 361 
combination therapy being cost effective at this threshold was 0.557, reflecting the 362 
uncertainty that continued use results in positive net health benefit. 363 
To address the uncertainty in the clinical effectiveness of liothyronine/levothyroxine 364 
combination therapy, the analysis quantified the value of conducting research, such as a 365 
definitive randomised controlled clinical trial. In monetary terms, and based on a population 366 
EVSI of £3.64m per year, the value of a clinical trial would be expected to exceed its cost 367 
within one year [37]. 368 
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Literature searches did not identify any health utility measurement [20] or economic 369 
evaluations of liothyronine. Judgements on its cost-effectiveness in the UK appear to be made 370 
implicitly in policy guidelines, driven in large part by the significant difference in the current 371 
unit acquisition cost between liothyronine and levothyroxine. Guidelines either consider 372 
liothyronine/levothyroxine combination therapy to be non-inferior to levothyroxine alone 373 
(based on the available weak clinical evidence), or to be inferior because of the shorter 374 
pharmacokinetic elimination half-life and safety concerns. Neither perspective is fully 375 
justified, as the current evidence base is not targeted to the specific population in question, 376 
and inferiority has not been demonstrated. Certainly, the pharmacokinetics of levothyroxine 377 
support more convenient, once daily dosing, and stable concentrations of free T3. 378 
Liothyronine, by contrast, requires frequent daily dosing which causes fluctuations in free T3 379 
that may have transient suppressive effects on TSH [38]. Although suppression of TSH 380 
(<0.03 mU/L) is associated with an increased risk of adverse cardiovascular outcomes [39] 381 
and mortality [18], a case-control study of patients taking long-term liothyronine found no 382 
evidence of additional risk of atrial fibrillation, cardiovascular disease or fractures, following 383 
adjustment for age [40]. The TSH concentrations of these patients were within normal range 384 
(median 1.07 mU/L). 385 
Our analysis had strengths in addressing a decision problem which is pertinent to the NHS 386 
across the UK. Generalisability to other countries might be limited, however, as the cost of 387 
liothyronine is highly variable (for instance, 28 tablets costs €2.30 in Greece, €3.90 in 388 
Portugal and €36 in The Netherlands). The methods are nonetheless applicable in other 389 
jurisdictions in cases of price inflation because of monopoly supply of an off-patent 390 
medicinal product, or when medicines are presumed to be of low value because of 391 
uncertainty in their clinical effectiveness. A value of information analysis in these contexts 392 
will help inform whether there is value in reducing uncertainty (e.g. by investing in further 393 
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research), or whether disinvestment is more appropriate. In acknowledging the limited 394 
evidence-base, we undertook a systematic approach to populate the model when direct 395 
evidence was not available. In particular, the analysis of responses to the survey of clinicians 396 
aimed to reflect the diversity of opinions in routine care, and not to achieve consensus, 397 
consistent with accepted methods [29]. There is considerable polarity in the views of 398 
prescribers with regards to the perceived benefits of liothyronine in the UK [41], and this was 399 
reflected in our analysis. While the mean probability of treatment response was 0.40, 38% of 400 
simulations had probabilities <0.1, and 20% >0.9. 401 
However, there are caveats to our analysis. First, the model is a simple representation of what 402 
is a complex clinical management problem. Patients may often be misdiagnosed or have co-403 
morbidities and experience multiple referrals, investigations and treatments. The decision 404 
analysis assumes patients are identified and eligible at the point of entry to the model. We 405 
further assumed that responders to liothyronine/levothyroxine combination therapy would 406 
experience the same population norm health utilities as patients who are treated successfully 407 
with levothyroxine. Second, we did not consider the influence of deiodinase 2 (DIO2) genetic 408 
polymorphisms. The CC genotype (rs225014) is a purported predictor of response to 409 
combination therapy [42]; however, this observation was based on a post hoc analysis, and 410 
has not been replicated in further studies. Third, our reliance on clinical opinions for 411 
estimates of resource utilisation may bias the analysis. Access to routine health 412 
administration data or estimates from clinical trials may be preferred, but these were 413 
unavailable. Responses to patient questionnaires may be biased for different reasons (e.g. 414 
self-selection, recall bias, lack of understanding of medical procedures and terminology) [43]. 415 
Finally, our surveys of patients and clinicians were potentially limited in terms of selection 416 
bias and alternative sampling methods may have been more reliable, although we are 417 
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unaware of any evidence to suggest that patient-reported resource use is more accurate than 418 
clinician-reported [43]. 419 
In conclusion, health technology reassessment provides a basis for informing important 420 
decisions concerning disinvestment, not only in relation to continued use, but also in relation 421 
to the value of conducting further research. It is widely appreciated that the deimplemention 422 
of low value medicines is more challenging than implementing new treatments, even when 423 
there are significant uncertainties surrounding their clinical effectiveness. In the case of 424 
liothyronine, our analysis suggests that while it might represent a cost-effective treatment 425 
option for patients who remain symptomatic with levothyroxine alone, a definitive clinical 426 
trial is necessary to confirm clinical effectiveness. This would be justified on the basis that 427 
the value of the information gained far exceeds the cost of a trial. 428 
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Figure 1. Distribution of responses to each dimension of the EQ-5D-5L. Levels 1-5 600 
correspond to increasing severity in each of the domains from a rater point of view, 5 being 601 
most severely affected 602 
 603 
  604 
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Figure 2. Cost-effectiveness plane (top) and cost effectiveness acceptability curve (bottom). 605 
Blue lines indicate the willingness to pay thresholds of £20,000 per QALY (filled) and 606 
£30,000 per QALY (dashed) and, in the cost effectiveness acceptability curve, the 607 






Table 1. Resource use and unit costs per intervention group, and according to treatment response 
Resource item Number of units Unit cost Reference 
 Levothyroxine and 
Liothyronine + 
levothyroxine (non-









subsequent years in 
responders >3 months) 
  
Thyroid hormone 
Levothyroxine 100μg daily 50μg daily 50μg daily £16.03 per year 16 






3.13 (2.47) 2.38 (2.31) 2.56 (1.29) £164 per visit 25 
General practitioner 5.56 (3.11) 1.81 (1.85) 2.44 (1.24) £37.40 per visit 28 
Phlebotomist 5.94 (6.00) 4.88 (6.51) 5.00 (6.22) £3.04 per sample 25 
Thyroid tests 
TSH 5.94 (6.00) 4.88 (6.51) 4.81 (6.32) £2.15 per test 16 
Free T4 5.94 (6.00) 4.88 (6.51) 5.00 (6.22) £2.10 per test 16 
Free T3 1.25 (1.60) 2.50 (2.33) 2.56 (1.68) £3.12 per test 16 
TRAb antibody testing 0.25 (0.46) 0.38 (0.52) 0.56 (0.90) £16.64 per test 16 
32 
 
TPO antibody testing 0.68 (0.70) 0.62 (0.74) 0.63 (0.74) £12.32 per test 16 
Safety monitoring 
Electrocardiogram 0.09 (0.08) 0.63 (0.52) 0.63 (0.52) £58 per test 25 
Echocardiogram 0.09 (0.08) 0.63 (0.52) 0.63 (0.52) £97 per test 25 
Bone densitometry 0.09 (0.08) 0.31 (0.46) 0.06 (0.07) £77 per test 25 




Table 2. Expected (mean) disaggregated 10-year costs (per patient) 













Thyroid hormone £160.30 £33,818.50 £1,001.76 
Healthcare professional 
Endocrinologist outpatient £5,125.00 £4,202.50 £5,386.38 
General practitioner £2,080.38 £911.63 £2,096.15 
Phlebotomist £180.50 £152.00 £190.81 
Thyroid tests 
TSH £127.66 £103.47 £134.95 
Free T4 £125.69 £105.00 £131.81 
Free T3 £39.00 £79.95 £45.83 
TRAb antibody testing £41.60 £93.60 £46.80 
TPO antibody testing £84.70 £77.00 £90.28 
Safety monitoring 
Electrocardiogram £50.75 £362.50 £85.73 
Echocardiogram £84.88 £606.25 £143.38 
Bone densitometry £67.38 £48.13 £89.75 
Total (undiscounted) £8,166.82 £40,560.52 £9,443.52 
Total (discounted at 3.5% 
per annum) 










(95% central range) 
Costs (deterministic) £19,082.25 £7,029.74 £12,052.50 
Costs (probabilistic) £18,990.83 £7,098.58 £11,892.25 (-£878 to £28,939) 
QALYs 
(deterministic) 
5.559 4.545 1.014 
QALYs 
(probabilistic) 
5.638 4.556 1.083 (-0.11 to 5.32) 
ICER (deterministic)   £11,880.65 per QALY 





Table 4. Results of one-way sensitivity analyses 
Parameter Estimate* ICER 
(£ per QALY gained) 
Probability of response 0.05 £20,816.64 
 0.1 £15,719.35 
 0.2 £13,170.70 
 0.6 £11,471.61 
Discount rate (costs) 0% £13,681.24 
 6% £10,838.31 
Discount rate (QALYs) 0% £10,300.84 
 6% £13,042.21 
Discount rate (costs and 
QALYs) 
0% £11,862.00 
 6% £11,897.95 
Time horizon (years) 1 £16,027.34 
 5 £11,754.63 
Cost of liothyronine (per annum) £100 £179.10 
 £1,000 £3,403.83 
 £10,000 £35,651.14 
Utility in symptomatic state 
based on EQ-VAS 
0.493 £10,544.94 
* Base-case vales are: probability of response 0.405, discount rate (costs and QALYs) 3.5% 
per annum, time horizon 10 years, cost of liothyronine £3,365.82 per year, and utility in 




Table 5. Parameter values for the probabilistic sensitivity analysis and value of information 
analysis 
Parameter Mean (SD) Distribution / notes 
Utility 
Asymptomatic (age 45-54) 0.85 (0.25) ~beta (1.626, 0.287) 
Asymptomatic (age 45-54) 0.80 (0.26) ~beta (1.765, 0.441) 
Symptomatic 0.53 (0.23) 1 – ~gamma (4.136, 0.114) 
Survival probability 
Age 45-54 0.9846 Fixed 
Age 55-64 0.9769 Fixed 
Resource use (non-drug) Mean (SD)* ~gamma (α, β) = (Mean2/SD2, SD2/Mean) 
Probability of response 0.405 (0.388) ~beta (0.242, 0.356) 
Eligible incident population 
(per year) 
100,000 Based on 3% of the UK population 
(66.65m) having hypothyroidism, and 5% 
of these not responding sufficiently to 
levothyroxine alone 
Uptake of liothyronine (per 
year) 
10% Assumption 
Size of future clinical trial (n) 300 Assumption 
*See table 1 for values. 
 
